Surrogate Endpoints Envisioned For Heart Failure Diagnostic Trials
This article was originally published in The Gray Sheet
Executive Summary
Medical device firms attempting to validate surrogate endpoints in clinical trials may benefit from early-stage collaborations with pharmaceutical companies, according to CDRH Cardiovascular Devices Branch Chief Bram Zuckerman, MD